The global heterozygous familial hypercholesterolemia (HEFH) market would reach US$58.54 billion by 2033. The amount has increased significantly from US$13.2 billion in 2022, indicating a 14.5% compound annual growth rate (CAGR). A genetic disorder called hypercholesterolemia (HEFH) is defined by elevated levels of low-density lipoprotein (LDL) cholesterol, commonly referred to as “bad cholesterol.” This cholesterol accumulation …